glp-1/gip/glucagon triple agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Courtesy ref no. 43-Schematic demonstrating
Description
95% CI 0.61, 1.10) [40]
The FDA still allows GLP-1 prescriptions, but only if you also have at least one qualifying health condition linked to your weight
Patients should also consider telemedicine platforms, which sometimes include discounted medications as part of their services
A patient walked into the clinic, excited about the 15 pounds theyd lost in two months on their new GLP-1 medication
While current FDA approvals for semaglutide are limited to diabetes and weight management, the potential cognitive benefits may influence prescribing decisions for at-risk patients
